Acurx Pharmaceuticals, Inc. has received United States Food and Drug Administration feedback that could allow a New Drug Application for investigational antibiotic ibezapolstat to be considered after one Phase 3 trial, provided the resulting clinical evidence is sufficiently robust. The Nasdaq-listed biotechnology company said the proposed IBZ-ASPIRE trial could also be structured to support indications covering both acute treatment of Clostridioides difficile infection and reduction of recurrence.
The development follows a Type C meeting held on July 13, 2026, with the meeting minutes forming the basis of Acurx’s August 3 regulatory update. It is an important clarification for the programme, but it is not an agreement that one trial will automatically be sufficient, an endorsement of ibezapolstat’s efficacy, or an indication that approval is likely.
The FDA instead left the decisive judgment until a future pre-New Drug Application meeting, when it can assess the totality of evidence from IBZ-ASPIRE, earlier studies, the planned IBZ-PATHFINDER trial in multiply recurrent disease and the complete safety package. That distinction matters because Acurx may have gained a potentially shorter regulatory route, but it has not received permission to lower the scientific standard applied to the pivotal study.
Why does the FDA’s one-trial discussion reduce Acurx’s burden without guaranteeing an ibezapolstat filing?
According to Acurx, the FDA said it would be open to discussing an application supported by one Phase 3 trial if the clinical results are persuasive and consistent. The agency is expected to consider the magnitude and robustness of efficacy, the generalisability of the findings to patients in the United States, their relevance to clinical practice, the supporting Phase 2 evidence and the adequacy of the safety database.
The fallback position remains clear. If IBZ-ASPIRE does not produce evidence meeting those expectations, the FDA has recommended a second trial consistent with the development plan discussed at Acurx’s April 2024 end-of-Phase 2 meeting. The new feedback therefore creates a conditional opportunity rather than a settled registration plan.
That position aligns with the FDA’s wider regulatory framework. Its May 2026 guidance for C. difficile drug development states that one adequate and well-controlled clinical investigation, together with confirmatory evidence, may be capable of meeting the substantial-evidence standard. Separate revised draft guidance issued in 2026 similarly describes the factors the agency may consider when deciding whether one rigorous study and supporting evidence are sufficient.
For Acurx, the possible advantage is substantial. Avoiding a second large international Phase 3 trial could reduce development costs, shorten the period before a potential filing and limit the additional financing required before regulatory review. The catch is that greater reliance on one pivotal study raises the importance of flawless execution, prespecified statistical control and a result that remains convincing across clinically relevant populations.
How could IBZ-ASPIRE test acute C. difficile treatment and recurrence reduction in one pivotal protocol?
IBZ-ASPIRE is planned as a randomised, active-controlled Phase 3 trial comparing ibezapolstat with oral vancomycin. Acurx expects approximately 550 patients in the modified intention-to-treat population, allocated on a one-to-one basis between the investigational antibiotic and the established comparator.
The initial analysis will examine whether ibezapolstat is non-inferior to vancomycin for clinical cure. If that requirement is satisfied, the programme would proceed to further analyses testing whether ibezapolstat is superior for reducing recurrence and potentially for clinical cure itself. The statistical sequence will be crucial because claims involving superiority cannot be inferred merely from favourable numerical differences.
FDA guidance recommends a 10-percentage-point non-inferiority margin for clinical-response studies using vancomycin as the active comparator. For programmes seeking both treatment and reduction-of-recurrence indications, the guidance calls for assessments of treatment success at the test-of-cure visit and sustained clinical response, defined through a follow-up period extending at least four weeks beyond treatment.
This framework gives Acurx a potentially valuable development proposition. Rather than positioning ibezapolstat only as another antibiotic capable of resolving an acute infection, the company is attempting to demonstrate that its microbiome-sparing profile can translate into fewer subsequent episodes.
That second proposition is clinically and commercially important, but it carries a higher evidentiary burden. Preserving bacterial diversity or producing favourable bile-acid changes may strengthen the biological rationale for reducing recurrence, but regulators will ultimately evaluate whether patients experience fewer recurrent infections, not whether laboratory markers simply move in an encouraging direction.
What does the published Phase 2 evidence show, and why is its small size still the central limitation?
The supporting Phase 2b study was randomised, double-blind, active-controlled and conducted across multiple United States centres. Thirty-two adults were assigned to receive ibezapolstat 450 milligrams twice daily or vancomycin 125 milligrams four times daily for ten days, with follow-up for recurrence after treatment. The study was subsequently published in The Lancet Microbe.
Among the evaluable participants, 15 of 16 patients receiving ibezapolstat achieved initial clinical cure, compared with 14 of 14 receiving vancomycin. Sustained clinical cure was reported in 15 of 16 ibezapolstat recipients and 12 of 14 vancomycin recipients, with no recurrence observed in the cured ibezapolstat group during the disclosed one-month follow-up.
Those findings provided a signal supporting further development, but they did not establish superiority. The difference in sustained clinical cure was not statistically significant, and the confidence interval was wide because the number of participants and recurrence events was small. In practical terms, Phase 2 showed that ibezapolstat could produce cure outcomes broadly comparable with vancomycin while generating a hypothesis about recurrence reduction. Phase 3 must now test that hypothesis at a scale capable of producing reliable estimates.
The published programme also reported microbiome and bile-acid findings that appeared consistent with reduced disruption of protective gut bacteria. Ibezapolstat inhibits a bacterial DNA polymerase target associated with certain Gram-positive organisms, giving it a narrower intended spectrum than many traditional antibiotics. The company believes that selectivity could help preserve organisms involved in converting primary bile acids into secondary bile acids, which are associated with resistance to C. difficile colonisation.
This mechanism is differentiated and scientifically relevant, but it remains supporting evidence. A favourable microbiome profile cannot substitute for prespecified clinical endpoints, particularly when the intended label includes reducing recurrence.
Safety will require similar caution. No drug-related serious adverse events were reported in the small Phase 2b dataset, while disclosed adverse events were generally mild. That provides early tolerability information, but the study was far too small to characterise uncommon adverse reactions or establish the safety profile expected for broader clinical use.
The FDA’s C. difficile guidance recommends that an application for treatment or recurrence reduction include at least 300 participants exposed to the proposed dose and duration. Acurx will therefore need to demonstrate that exposure from IBZ-ASPIRE and its supporting trials produces an adequate registration safety database, not merely a successful efficacy analysis.
Why could IBZ-PATHFINDER support the recurrence claim without replacing controlled Phase 3 evidence?
Acurx has initiated start-up work for IBZ-PATHFINDER, an open-label Phase 2 pilot study expected to enrol as many as 20 patients who have experienced at least three C. difficile episodes within the preceding 12 months. The company expects initial enrolment during the fourth quarter of 2026.
This population represents a severe clinical challenge because the likelihood of another episode increases after repeated recurrences. Studying ibezapolstat in these patients could show whether its activity and tolerability remain consistent in a group whose disease history differs considerably from that of many first-episode patients.
The trial may also provide useful confirmatory evidence for the recurrence component of a future application. The FDA specifically acknowledged that successful IBZ-PATHFINDER data could support the overall submission alongside IBZ-ASPIRE.
Its limitations, however, are built into the design. A 20-patient, open-label study without a concurrent control cannot independently quantify how much ibezapolstat changes recurrence risk relative to vancomycin, fidaxomicin or another regimen. Patient selection, prior treatment and the natural variability of multiply recurrent disease can all influence the outcome.
IBZ-PATHFINDER should therefore be viewed as a supporting and programme-shaping study. Its greatest value may be in demonstrating consistency, informing the management of high-risk patients and strengthening the totality of evidence, rather than serving as a substitute for the randomised comparison in IBZ-ASPIRE.
How would ibezapolstat enter a treatment market shaped by vancomycin, fidaxomicin and microbiome products?
The clinical environment has evolved beyond a simple comparison with vancomycin. Current Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidance conditionally favours fidaxomicin over a standard course of vancomycin for an initial C. difficile episode, while recognising vancomycin as an acceptable alternative. Fidaxomicin is also suggested for recurrent episodes, although resource availability and acquisition cost can affect implementation.
Patients with repeated recurrence may receive tapered vancomycin regimens, fidaxomicin, faecal microbiota transplantation or microbiota-based products after antibacterial treatment. The FDA has approved products including Vowst for preventing recurrence in adults following antibacterial treatment for recurrent infection. These interventions do not necessarily compete with ibezapolstat in identical settings, but they shape expectations around sustained response and microbiome restoration.
Ibezapolstat’s proposed commercial distinction would be the possibility of addressing the active infection and lowering recurrence risk with the same orally administered antibiotic course. That could reduce the need for a separate recurrence-prevention intervention for some patients, but only if Phase 3 data demonstrate a clinically persuasive difference and the final label supports such use.
Adoption would also depend on pricing, formulary placement, susceptibility patterns, guideline inclusion and real-world evidence. A product does not become a preferred first-line antibiotic merely by matching an inexpensive comparator. Acurx would need to show that any premium cost is justified by fewer recurrences, lower downstream healthcare utilisation or meaningful advantages for selected patients.
Why could financing remain as important as regulatory clarity for Acurx’s Phase 3 execution?
Acurx has repeatedly stated that the start of the international IBZ-ASPIRE programme is subject to obtaining appropriate funding. That qualification is central to the story because a 550-patient, multicentre Phase 3 trial will require resources substantially beyond those needed for the small Phase 2 programme.
At March 31, 2026, Acurx reported approximately US$9.3 million in cash, a quarterly net loss of US$1.7 million and operating cash use of about US$1.4 million. Its quarterly filing said existing resources were not expected to cover anticipated requirements for at least 12 months and identified substantial doubt about the company’s ability to continue as a going concern without additional capital.
The company subsequently raised approximately US$2.5 million in gross proceeds through an April equity transaction. That financing supported operations but also expanded the share count, illustrating the dilution risk faced by shareholders when a small biotechnology company moves toward expensive pivotal development.
Acurx shares traded around US$1.44 during early August 3 activity, leaving the stock close to the bottom of a 52-week range of approximately US$1.33 to US$8.34. The company’s market capitalisation was about US$6.2 million, reflecting a market that continues to assign considerable risk to financing, execution and eventual commercialisation despite the regulatory progress.
Recent performance has also remained subdued. The shares were roughly 7% below their June 30 close and only modestly above late-July levels. The regulatory update is best interpreted as a de-risking event for trial planning rather than a resolution of the company’s capital requirements.
A licensing partnership, regional collaboration, strategic investment or larger equity raise could materially change the programme’s execution outlook. Until one of those routes is secured, the theoretical savings from a possible single-trial registration strategy will not by themselves place IBZ-ASPIRE into active enrolment.
What does the FDA update change, and which ibezapolstat milestones now carry the most weight?
The August feedback gives Acurx a more coherent regulatory path. IBZ-ASPIRE can be designed around a vancomycin-controlled non-inferiority test for acute cure, followed by superiority analyses intended to support recurrence reduction, while IBZ-PATHFINDER contributes evidence from multiply recurrent disease.
What the update does not provide is equally important. It does not confirm that one trial will be accepted, validate a recurrence benefit or remove the possibility of a second pivotal study. It also does not resolve how Acurx will finance international Phase 3 execution or commercial preparations.
The next meaningful tests will be the financing of IBZ-ASPIRE, initiation and enrolment of IBZ-PATHFINDER, disclosure of the final statistical framework and evidence that the safety database can meet FDA expectations. Acurx’s second-quarter business update, scheduled for August 14, may provide an early indication of whether regulatory clarity is being converted into operational progress.
Ibezapolstat now has an unusually focused opportunity: demonstrate that a selective antibiotic can resolve an acute C. difficile infection without creating the biological conditions that favour another episode. The FDA has given Acurx room to pursue that proposition within one pivotal programme, but IBZ-ASPIRE will need to deliver the kind of result that makes a second trial unnecessary rather than merely inconvenient.
